vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $13.3M, roughly 1.4× Laird Superfood, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -90.7%, a 77.5% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 15.0%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
LSF vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $19.1M |
| Net Profit | $-1.8M | $-17.4M |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | -186.1% |
| Net Margin | -13.2% | -90.7% |
| Revenue YoY | 15.0% | 740.1% |
| Net Profit YoY | -341.4% | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.0M | $19.1M | ||
| Q1 25 | $11.7M | — | ||
| Q4 24 | $11.6M | $12.8M | ||
| Q3 24 | $11.8M | $29.1M | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-975.1K | — | ||
| Q2 25 | $-362.2K | $-17.4M | ||
| Q1 25 | $-156.2K | — | ||
| Q4 24 | $-398.4K | $-92.2M | ||
| Q3 24 | $-166.1K | $-16.6M | ||
| Q2 24 | $-239.1K | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | — | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | -3.3% | -186.1% | ||
| Q1 25 | -1.9% | — | ||
| Q4 24 | -4.1% | -338.5% | ||
| Q3 24 | -2.3% | -85.9% | ||
| Q2 24 | -3.4% | — | ||
| Q1 24 | -11.0% | — |
| Q4 25 | -13.2% | — | ||
| Q3 25 | -7.6% | — | ||
| Q2 25 | -3.0% | -90.7% | ||
| Q1 25 | -1.3% | — | ||
| Q4 24 | -3.4% | -721.7% | ||
| Q3 24 | -1.4% | -57.2% | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | -10.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $778.5M |
| Total Assets | $19.2M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $3.9M | $739.2M | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $8.3M | $834.2M | ||
| Q3 24 | $7.9M | $422.7M | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $11.5M | — | ||
| Q3 25 | $12.8M | — | ||
| Q2 25 | $13.4M | $778.5M | ||
| Q1 25 | $13.3M | — | ||
| Q4 24 | $13.2M | $757.5M | ||
| Q3 24 | $13.1M | $378.9M | ||
| Q2 24 | $12.6M | — | ||
| Q1 24 | $12.7M | — |
| Q4 25 | $19.2M | — | ||
| Q3 25 | $18.9M | — | ||
| Q2 25 | $20.4M | $815.1M | ||
| Q1 25 | $21.5M | — | ||
| Q4 24 | $19.3M | $864.6M | ||
| Q3 24 | $18.8M | $439.2M | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $17.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $-2.8M | $-37.7M | ||
| Q1 25 | $-1.3M | — | ||
| Q4 24 | $339.2K | $-37.5M | ||
| Q3 24 | $305.8K | $-12.5M | ||
| Q2 24 | $642.7K | — | ||
| Q1 24 | $-422.3K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
NAMS
Segment breakdown not available.
